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~bstraet Azide and hydroxylamine release nitric oxide (NO) 
enzymatically in biological conditions. We observed that both 
compounds were able to inhibit in vitro the programmed cell death 
~ff human eosinophils from peripheral blood. This protective ffect 
could be mimicked by permeable cGMP analogs and by the 
pbospbodiesterase inhibitor 3-isobutyl-l-methylxanthine. More- 
over, the soluble guanylate cyclase inhibitor LY-83583 inhibited 
in a dose-response manner the effects of the NO donors. Conse- 
quently, via the increase of eosinophil survival, NO could contrib- 
ute to the amplification of inflammatory and allergic processes. 
Fhis effect appears to be mediated, at least in part, by the soluble 
guanylate pathway. 
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1. Introduction 
Eosinophils are thought o play an important role in many 
allergic diseases uch as allergic rhinitis, bronchial asthma or 
atopic dermatitis [1]. Under such circumstances, eosinophils 
infiltrate the tissues and release mediators (eosinophil cationic 
proteins, paf-acether and leukotriene C4) which are responsible 
for tissue damages and inflammation [2]. Therefore, the knowl- 
edge of the factors which regulate the survival of eosinophils 
in tissues is important for the understanding of allergic diseases. 
Some cytokines and mediators (e.g. IL-3, IL-5 or GM-CSF), 
possibly present in inflamed tissues, have been shown to in- 
crease eosinophil half-life in vitro by inhibiting eosinophil ap- 
optosis [3]. In this article, we propose that nitric oxide (NO) - 
a free radical derived from the oxidative metabolism of arginine 
- is able to up-regulate eosinophil survival. 
Although there is a growing interest for NO in immunology 
and in inflammation [4], the possible effects of NO on the 
physiology of the eosinophils remain to be studied. Among the 
cells involved in inflammation, the synthesis of NO by murine 
macrophages has been clearly established [5]. However, NO 
synthesis by neutrophils and by human macrophages i  ques- 
tioned [6--8]. In human, NO has been shown to down-modulate 
T cell proliferation [9], to activate peripheral blood mononu- 
clear cells [10], to inhibit neutrophil degranulation [11], but to 
increase the release of TNF-a  by neutrophils [12]. 
Azide and hydroxylamine g nerate NO in a well-documented 
enzymatic reaction catalyzed by endogenous catalase [13,14]. 
In this paper we report the effects of these two compounds on 
the survival of human eosinophils in vitro. We propose that NO 
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is able to increase the eosinophil viability and that activation 
of the soluble guanylate cyclase pathway could up-regulate the 
eosinophil survival. 
2. Materials and methods 
2.1. Reagents 
Azide (Merck, Darmstadt, Germany), hydroxylamine hydrochlo- 
ride, 3-isobutyl-l-methylxanthine, dibutyryl-cGMP, 8-bromo-cGMP 
(Sigma, Saint-Louis, MO, USA), dibutyryl-cAMP, LY-83583 (Biomol, 
Plymouth Meeting, PA, USA) were obtained as mentioned. 
2.2. Human blood eosinophil preparation 
Human blood eosinophils from healthy donors were isolated using 
Percoll gradients as described [15]. Venous blood was obtained from 
the local Center for Blood Transfusion. The granulocyte population 
was recovered by dextran sedimentation a d centrifugation through 
Percoll (d = 1.077). After washing, the residual erythrocytes were elimi- 
nated by hypotonic lysis. The cell suspension was resuspended in RPMI 
medium at a concentration f 50 x l0 b cells/ml. Two ml of this cell 
suspension were layered on a Percoll gradient (l.080, 1.085, 1.090, 
1.095, 1.105) and centrifuged at 600×g for 30 min. The cells were 
harvested from the bottom through a pinhole and collected in 500 fll 
fractions. Cytocentrifuge smears of the different fractions were pre- 
pared, fixed in methanol and stained by Wright's tain (kit RAL 555, 
Prolabo, Paris, France). The eosinophil percentage was assessed for 
each fraction and fractions with >95% eosinophils were pooled. The 
only contaminating cells were neutrophils. The ability of freshly iso- 
blated eosinophils to exclude Trypan blue was >98%. 
2.3. Cell culture 
Freshly isolated eosinophils (2 ~, × l0 s cells/ml) were suspended in
RPMI 1640 (Gibco BRL) supplemented with 0.1 mM non-essential 
amino-acids, 100 U/ml penicillin, 100 /lg/ml streptomycin, 10 mM 
HEPES, 2 mM L-glutamine and 10% (v/v) fetal calf serum. Aliquots of 
180/A were placed into 96-well fiat-bottomed microtiter plates (Costar, 
Cambridge, MA, USA) containing 20/ll of compound to be tested at 
defined concentrations or diluting medium alone. The plates were main- 
tained at 37°C in a 5% CO: atmosphere for 48 h. 
2.4. Viability and cytology of apoptotie osinophils 
The viability of the eosinophils was assessed by Trypan blue exclu- 
sion. The percentages of viable cells were calculated over the number 
of viable cells present at the beginning of the culture (i.e. around 100% 
of viable cells). 
Cytocentrifuge slides were stained as described above in cell prepara- 
tion section and were examined under a light microscope ( x 400) using 
oil immersion. The proportion of eosinophils exhibiting morphologic 
features of apoptotis was assessed as previously described [16]. Briefly, 
alter 24 h of incubation, apoptotic eosinophils showed nuclear pycnosis 
and cytoplasmic condensation. I  some eosinophils, the limit between 
nucleus and cytoplasm vanished. At 48 h, these effects were more 
marked, affecting increasing numbers of eosinophils. Moreover, the cell 
size decrease was particularly marked and frequently no nucleus was 
visible. The apoptotic eosinophil appeared then as a 'granule bag'. At 
least 200 cells were examined for each slide. 
2.5. Eleetronie volume analysis 
An aliquot of the cells was diluted in phosphate-buffered saline and 
the volume distribution ofthe eosinophils was determined by electronic 
analysis using a Coulter Counter (model ZM) coupled to a Channelyzer 
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(Coulter Electronics, Hialeah, FL, USA) [17]. The following settings 
were used: gain 1, attenuation 2,aperture current 1,000/.tA, aperture 
140 pro, lower threshold 3.5, upper threshold 100. The instrument was 
calibrated with latex microspheres (Coulter) to allow calculation of 
absolute volumes. 
As previously described, eosinophils underwent a strong volume 
decrease (approximately 60%) during apoptosis [16]. Therefore, small 
apoptotic eosinophils and normal volume osinophils appeared as well- 
separated populations with mean volumes of 150 and 400/gm 3.The 
limit between shrunken and normal volume populations was fixed at 
300//m 3 [16]. 
2.6. DNA fragmentation 
The DNA fragmentation f eosinophils was evidenced as described 
[18]. Briefly, purified eosinophils (I-2 × 106 cells) were washed in phos- 
phate-buffered saline at 4°C and resuspended in lysis buffer (NaC1100 
raM, Tris 10 mM, EDTA 1 raM, sodium N-lauroyl-sarcosine 1%, pH 
8) containing proteinase K (0.2 mg/ml) (Sigma). The suspensions were 
incubated overnight at 37°C and the DNA was twice extracted with 
phenol and 24:1 chloroform/isoamyl alcohol (1 : 1, v/v). Sodium acetate 
was then added (0.3 M final) and the DNA was precipitated in 80% final 
ethanol. The DNA precipitates were recovered by centrifugation, air 
dried and resuspended in 20/ll of Tris-EDTA buffer. Two/.tl of loading 
buffer was added to each sample. Electrophoresis was performed at 
6 V/cm of gel in Tris-EDTA-acetate buffer. After electrophoresis, DNA 
was visualized by soaking the gel in distilled water containing l/.tg/ml 
ethidium bromide. 
2. 7. Statistical analysis 
Statistical nalysis was performed by using the Student's t-test for 
paired variates. Differences were considered to be statistically signifi- 
cant when P < 0.05. 
3. Results 
3.1. EfJect of azide and hydroxylamine on the survival in culture 
of human eosinophils 
In the absence of added cytokine, eosinophils in culture un- 
dergo a program of cell death via an apoptotic process. The cell 
death and the apoptosis were evidenced and quantified by four 
parameters: Trypan blue exclusion, morphological examina- 
tion using light microscopy, cell volume measurement and 
DNA fragmentation. In our culture conditions, in control 
wells, 24.5 + 2.9% of the eosinophils present at the beginning 
of the culture still excluded Trypan blue after 48 h of culture 
(Fig. 1A). Conversely, 81.6 + 2.0% of the eosinophils present 
in the culture were apoptotic, as judged by cytological examina- 
tion (Fig. 1B and Fig. 2B) and 67.0 + 3.4% were shrunken as 
measured by electronic ell sizing (Fig. 1C and Fig. 2A). The 
hallmark of apoptosis, namely the DNA fragmentation with a 
ladder pattern, was present (Fig. 3). 
In the presence ofazide (1 300pM) or hydroxylamine (0.01- 
1 raM), the survival of eosinophils was increased. This effect 
was dose-dependent wi h an optimal effect at 100 pM and 300 
pM, for azide and hydroxylamine r spectively. Indeed, after 48 
h of culture, 61.9 + 6.6% (P < 0.001) of the eosinophils present 
at the beginning of the culture were viable in the presence of 
100/.tM azide and 64.8 + 8.2% (P < 0.01) in the presence of 300 
pM hydroxylamine vs. 24.5 + 2.9% in the presence of the dilut- 
ing medium alone (Fig. 1A), This was paralleled by a decrease 
of the percentages of apoptotic and shrunken eosinophils pres- 
ent in the culture (Fig. 1B and Fig. 1C). Moreover, the DNA 
fragmentation was markedly reduced in the presence of azide 
or hydroxylamine at optimal concentration (Fig. 3). 
3.2. Guanylate cyclase pathway and eosinophil apoptosis 
Guanylate cyclase is one of the most important target for 
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Fig. 1. Effect of azide, hydroxylamine, db-cGMP and IBMX on eosin- 
ophil viability and apoptosis, purified human eosinophils from periph- 
eral blood were incubated (24 × 105 cells/ml) in the presence ofazide 
(100/tM), hydroxylamine (300/.tM), db-cGMP (1 mM), IBMX (1 raM) 
or diluting buffer alone as control. After 48 h, the percentages of viable 
eosinophils remaining in the culture (A), the percentages of shrunken 
(B) and apoptotic (C) eosinophils present in the culture were assessed 
as described in methods. In this figure and the followings, the results 
are given as means _+ S.E.M. of independent experiments with different 
donors. The numbers of experiments are indicated between parenthesis. 
*P < 0.01, **P < 0.001 as compared to control values. 
NO. We thus tempted to mimic the effect of NO donors by 
adding permeable analogs of cGMP. Dibutyryl-cGMP (db- 
cGMP; 1 mM) significantly increased the number of eosino- 
phils excluding Trypan blue and decreased the percentages of
apoptotic and shrunken eosinophils (Fig. 1). The same results 
were obtained with 8-bromo-cGMP (1 mM) (data not shown). 
IBMX (3-isobutyl-l-methylxanthine) is a phosphodiesterase 
inhibitor and thus it increases the concentration f the cyclic 
nucleotides in the cell by decreasing their degradation. As 
shown in Fig. 1, IBMX inhibited eosinophil shrinkage, osino- 
phil apoptosis and increased eosinophil viability. However, 
IBMX is a non-specific nhibitor of phosphodiesterases andthe 
observed effect could be due to an increase of cAMP. Indeed, 
in the same experimental conditions, dibutyryl-cAMP in- 
creased apoptosis (data not shown). This strongly suggested 
that the protective ffect of IBMX was linked to an increase of 
cGMP levels. 
LY-83583 is an inhibitor of NO-mediated soluble guanylate 
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cyclase activation [19]. LY-83583 (1-30/aM) inhibited, in a 
dose-response manner, the effect of azide 100/,tM (Fig. 4). The 
ICs0 for inhibition of the azide effect was approximately 1-3 
pM. This agrees with the ICs0 of LY-83583 (2/tM) previously 
reported for guanylate cyclase inhibition [19]. Inhibition by 
1 Y-83583 of the hydroxylamine effect on eosinophil survival 
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Fig. 2. Inhibition of the morphological features of apoptosis neosino- 
phils treated by NO donors. The morphological changes associated 
with apoptosis are characteristics in eosinophils (A): at 48h, most of the 
eosinophils appeared as 'granule bags' without visible nucleus truc- 
tures. In some cells, a pycnotic nucleus was still visible. Moreover, the 
cell volume was strongly reduced. This latter characteristic was pre- 
cisely measured by electronic ell sizing. The population i dashed line 
is the volume distribution of the eosinophils at the beginning of the 
culture (B). In the presence of azide (100/aM) or hydroxylamine (300 
/aM), the percentages ofeosinophils exhibiting the features of apoptosis 
(C,E) and the percentages ofshrunken eosinophils (D,F) were strongly 
reduced. 
Fig. 3. Electrophoresis ofDNA from eosinophils treated by azide and 
hydroxylamine. Agarose gel electrophoresis of DNA extracted from 
2 x 106 eosinophils was performed at the initiation of the culture (lane 
A) or after a 48 h-culture in the presence of the diluting buffer alone 
(lane B), azide 100/aM (lane C), hydroxylamine 300 pM (lane D). Lanes 
W show the migration of MHindIII digested fragments. 
In this article, we show that azide and hydroxylamine are 
able to increase the viability of cytokine-deprived osinophils 
in culture as evidenced by Trypan blue exclusion, and to inhibit 
the eosinophil apoptosis as evidenced by the classical parame- 
ters of apoptosis (characteristic morphological modification, 
DNA fragmentation). Azide and hydroxylamine are NO do- 
nors in biological conditions. Indeed, azide or hydroxylamine, 
in the presence of endogenous catalase and H202, give a NO- 
heme complex which is able to activate guanylate cyclase [13]. 
Although due to low numbers of eosinophils in healthy 
human donors - we were unable to measure directly the cy- 
tosolic cGMP, our experiments with LY-83583 (Fig. 4) strongly 
suggested that guanylate cyclase was involved in the present 
model. Indeed, LY-83583 has been reported to be a specific 
inhibitor of NO-mediated soluble guanylate cyclase activation 
and we calculated an ICs0 compatible with inhibition of guanyl- 
ate cyclase [19]. Furthermore, both permeable analogs of 
cGMP and IBMX mimicked the effect of NO. Although we 
cannot rule out other targets for NO, the activation of guanyl- 
ate cyclase appears to be an important mechanism for eosino- 
phil survival. 
Both cytotoxic and cytoprotective properties have been re- 
ported for NO, Thus, NO has been shown to be responsible for 
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Fig. 4. Effect of the soluble guanylate cyclase inhibitor LY-83583 on 
eosinophil survival and apoptosis. Purified human eosinophils were 
incubated (2 x 105 cells/ml) in the presence of azide 100/.tM with defined 
concentrations of LY-83583. After 48 h, the percentages of remaining 
viable cells and the percentages ofnon-apoptotic eosinophils were as- 
sessed (n = 3). 
activation [20, 21] and for the apoptosis of murine mastocy- 
toma cells [22]. In neuronal cells, exogenous NO released from 
NO donors, was shown, according to the environmental redox 
potential, to have either protective or cytotoxic properties. Cy- 
totoxic properties were thought o be due to the formation of 
peroxynitrites whereas cytoprotective properties appeared to 
be due to the S-nitrosylation of a membrane receptor [23]. In 
other systems, NO has been shown to protect from the cellular 
damages induced by the reactive oxygen species [24]. Since 
some compounds which react with the reactive species of oxy- 
gen have a protective ffect [25], one could speculate that, in 
our experiments, NO also forms intermediate products with 
reactive species of oxygen and thus indirectly protects eosino- 
phils from deleterious effects of reactive oxygen species by 
diverting them from their usual targets. However, the simulta- 
neous addition of superoxide dismutase and catalase to the 
eosinophil cultures did not inhibit apoptosis (unpublished 
data). Thus, this indirect mechanism does not seem to be at 
work in our system. 
In contrast with azide and hydroxylamine which release NO 
enzymatically, other NO donors spontaneously release NO in 
physiological conditions (e.g. S-nitroso-N-acetyl-penicillamine, 
S-nitroso-cysteine, SIN-l). We have also used such com- 
pounds, but the cGMP-dependent protective ffect of NO on 
eosinophils appeared to be counteract by cytotoxic effects (data 
not shown). These NO donors, however, release NO in a rela- 
tively short time as compared to the culture length. Thus, a 
tempting hypothesis could be that eosinophil protection is ob- 
tained at best by low NO doses released continuously (for 
example, when NO is released enzymatically in the presence of 
E Beauvais et al./FEBS Letters 361 (1995) 229 232 
azide and hydroxylamine). In contrast, a burst of high amounts 
of NO from compounds uch as SIN-1 should lead to eosino- 
phil injury. Experiments aimed to measure the kinetics of NO 
release from these two types of NO donors have been under- 
taken in the eosinophil model to address this question. 
In conclusion, our results uggest an important role for both 
the soluble guanylate cyclase pathway and its natural agonist 
NO in inflammation and allergy by increasing eosinophil sur- 
vival. 
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